Josh, who suffers from advanced gastroduodenal cancer, traveled to China after exhausting conventional treatment options in his home country. His eligibility for the therapy was confirmed following biomarker testing that showed Claudin 18.2 positivity and HER2 negativity. Having completed the initial stage of leukapheresis, the patient now awaits the reinfusion of his manufactured CAR-T cells, which is expected to take place within the coming weeks.

This development arrives shortly after the formal approval of Satri-cel, the world's first CAR-T therapy specifically indicated for solid tumors. Dr. Linli Xuan, Chief of Medical Oncology at the center, noted that the facility is increasingly functioning as a primary destination for global patients seeking access to therapies developed within China. The center manages this influx through a dedicated international office, providing multilingual coordination and logistical support to navigate the complexities of advanced cellular immunotherapy.